ArticleBMC cancer2014
DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
Javier Martinez-Useros et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
20 papers cite it
this papercites it